帕金森病患者血清cys C、UA、Hcy、NSE水平与病情严重程度的相关性分析

doi:10.3969/j.issn.1671-7171.2024.05.012

Abstract
Figure/Table
References
Related Citation (15)

Download: PDF (1219 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract 【Objective】To explore the correlation of the severity of Parkinson's disease with the serum levels of cystatin C (cys C), uric acid (UA), homocysteine (Hcy), and neuron-specific enolase (NSE).【Methods】A retrospective analysis was conducted on the clinical data of 120 Parkinson's disease patients. Patient demographics, lipid profiles, coagulation markers, and levels of cys C, UA, Hcy, and NSE were statistically analyzed. Multivariate logistic regression was used to identify independent risk factors affecting the severity of the disease, while the Spearman test was utilized to analyze the correlation between these biomarkers and disease severity.【Results】Of the 120 patients, 43 (35.83%) were in the early stage of the disease, classified as the early group; the remaining 77 (64.17%) were in the middle to late stages, classified as the middle-late group. Comparisons of disease duration, age, gender, hemoglobin, platelets, coagulation markers, blood pressure, and lipid levels between the groups showed no statistically significant differences (P>0.05). The levels of cys C, Hcy, and NSE were significantly higher in the middle-late stage group compared to the early stage group (P<0.05), while UA level in the middle-late stage group was lower than that in the early stage group (P<0.05). Multivariate logistic regression analysis indicated that cys C, Hcy, and NSE were independent risk factors for the severity of Parkinson's disease (P< 0.05), whereas UA served as a protective factor (P<0.05). Spearman test results showed a positive correlation of disease severity with levels of cys C, Hcy, and NSE, while a negative correlation of the severity with UA (P<0.05).【Conclusion】cys C, Hcy, and NSE are risk factors that affect the severity of Parkinson's disease, while UA acts as a protective factor. The levels of these biomarkers are closely related to the severity of the condition, which should be paid good attention clinically.

Key words： Parkinson Disease Chalones/BL Uric Acid/BL Cysteine/BL Phosphopyruvate Hydratase/BL

Received: 10 December 2023

PACS:

R742.5

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	GUO Lina
	ZHAO Xiaoling
	WANG Yanrui

Cite this article:

GUO Lina,ZHAO Xiaoling,WANG Yanrui. Correlation of the Severity of Parkinson's Disease with Serum Levels of cys C, UA, Hcy, and NSE[J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(5): 685-687.

URL:

http://journal07.magtech.org.cn/yxlcyj/EN/10.3969/j.issn.1671-7171.2024.05.012 OR http://journal07.magtech.org.cn/yxlcyj/EN/Y2024/V41/I5/685

[1] 赵雪薇,陈珮琪,牛延翔,等. 帕金森病的病因及发病机制研究进展[J].新乡医学院学报,2021,38(4):378-381.
[2] BALASH Y,KORCZYN A D,MIGIROV A A,et al. Quality of life in Parkinson's disease: a gender‐specific perspective[J].Acta Neurol Scand,2019,140(1):17-22.
[3] 赵秀鑫,任惠. 帕金森病与炎症相关的研究进展[J].中国现代医学杂志,2022,32(1):52-56.
[4] 中华医学会神经病学分会帕金森病及运动障碍学组,中国医师协会神经内科医师分会帕金森病及运动障碍专业. 中国帕金森病的诊断标准(2016版)[J].中华神经科杂志,2016,49(4):268-271.
[5] 李哲.帕金森病[M].苏州:江苏科学技术出版社,2011:98-101.
[6] 白荣荣,唐亚丽,佘腊珍,等. A型肉毒毒素治疗帕金森病研究进展[J].中华神经科杂志,2022,55(1):70-76.
[7] 杨静,董海蓉,戚志强,等. 帕金森病患者血清同型半胱氨酸水平与病程和病情严重程度的相关研究[J].中华老年心脑血管病杂志,2019,21(7):762-763.
[8] VILLUMSEN M, AZNAR S, PAKKENBERG B,et al. Inflammatory bowel disease increases the risk of Parkinson's disease: a Danish nationwide cohort study 1977-2014[J].Gut,2019,68(1):18-24.
[9] 常庆庆,李红燕. 帕金森病患者血脂、胱抑素C及同型半胱氨酸水平分析[J].中国临床神经科学,2018,26(5):495-501.
[10] 刘春苗,程启惠. 胱抑素C、同型半胱氨酸与帕金森病病情进展的相关性研究[J].重庆医学,2016,45(26):3700-3702.
[11] 李欣,范国锋,陆健辉,等. 血清神经元特异性烯醇化酶与老年帕金森病患者认知功能障碍的相关性[J].中国老年学杂志,2019,39(14):3455-3458.
[12] 张家和,柯开富,施建生,等. 血尿酸、cys C及Hcy与老年帕金森病患者病程及疾病严重程度相关性分析[J].中国医药导报,2022,19(5):82-85.
[13] 肖雪洋,武治印,胡琳珍. 帕金森发病机制及其最新治疗策略[J].湖北大学学报(自然科学版),2021,43(5):514-521.

[1]	. [J]. JOURNAL OF CLINICAL RESEARCH, 2024, 41(6): 940-942.